{"name":"Neuropore Therapies Inc.","slug":"neuropore-therapies-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQRHJtakxvdkRYZ3J2azgyVWJiMVJpdDNZSFBQbEFfakVCcjZ0dUsydlVOMTlxa2pFdUdVengtendsdmJ2UG9nYzB5aVBJc1pYMmJwbnVkeTdlZ0xEMDRVVVBrYnFrN1lsNmo4VGlKdkdCSnV0c3VkdzlmRFluXzgtbmVNQURBNFpKa00tZDlWeXBod3hLR3ExTmpLbUxRTGFkMThDV0FmMk54VHJpeEhWbzRoSEhXVUlsYi1Ca2QyV3dPbWxvV0ZqMGFqbnN4Rk5Wd3N6ZUZ0dVR1MGpMdzF6eFhLN1l2a1MxbnFock1VU0ZMY0RHRTBHUmVB?oc=5","date":"2026-04-02","type":"trial","source":"Barchart.com","summary":"Motor Neuron Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveInsight - Barchart.com","headline":"Motor Neuron Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPbnpLNGxqM1dUX3VWbkJEaWZ1dzY2SWhEUEY3am5VSkNGS1U1czl6S1JKbklnOW9CbzdOZzloQnZLSTFBMnY1TzVIN1AtNFJ3SmhXSUcxRFowTXRDenpkZFlKRmt2cEhRc2QzcFRPMU54dG40bmZoWVF4SUVrNlNhWHNpVnA0LVRrak84MjBpUmRCUk0?oc=5","date":"2025-03-20","type":"regulatory","source":"openPR.com","summary":"Parkinson's Disease Pipeline 2025: FDA Updates, Therapy - openPR.com","headline":"Parkinson's Disease Pipeline 2025: FDA Updates, Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOZWN0REtXZE1JU3haVDU5YUlYaGRWSm5EVzRVc0FtR1hTMWduT3NfVUJqVkJJdDRaay1DTlIyaDZqRmVZWTBadnZzS1pWT3NKVUozSTdqXzZxc1B5VFNRZU1QdlM0elB3b2JPXzMwS0NBVGhkb25RdmJiQ2RaeXoyNHRLWHhGWDRGdVVVNFM2R2UyZFFCNVlOcmlLMGV6SHVMemp0YnhkSGhZalRKOGtTUGxTRmxWR1Jvb2lUU0tR?oc=5","date":"2024-09-26","type":"pipeline","source":"Science | AAAS","summary":"Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades? - Science | AAAS","headline":"Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades? - Science | AAAS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOZ01rVGpjb2lSMXVDLTVnQ2pZcGExVHNWQkpFcENrOEJGLWtPT1FZb0RpYzRVOF92RTRIQjB1bm5VR1k1Vm9GdkJOOG92OTFjVy1oVTZ6NmlFUWhIcTlQVmhjU25yQUhvNFhmNmVYMmxkX0RKLTRMWU11dVdELVBUaHFwbXlVMFRLZ0pYbU52dmdNbFQtZUQ5emFWTU4tTWoySHgtZXF1UUl2Qlc1dTJJVEpDNlBNUVZMaUNDbXpzQ3gzYThVZGc?oc=5","date":"2024-09-26","type":"pipeline","source":"fiercebiotech.com","summary":"NIH neuroscience leader committed research misconduct, agency investigation finds - fiercebiotech.com","headline":"NIH neuroscience leader committed research misconduct, agency investigation finds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9DdEowWFZFWWN0R0VWN2ZJcXVoWk5FdERzY0F5T0FiN1VKcWswcHA2N2l4T294RGFtSDEtb2U2S2owRHJGQWhDWUVGTFhtM2lGQ1NkYmN4N0Y0WWVmazNj?oc=5","date":"2023-07-17","type":"pipeline","source":"Nature","summary":"In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease - Nature","headline":"In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s dis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQUkR5NW9Ub2ZoOEQxUi1SRkJXMGl1Nmw1V0JKTzJrMHVVeUNpVHlNMVgzTTBQT1FNNjJEWUEyWEZvZ1JFcFozR1JNRU5NRk1XYjZXQTBBRVRWamEtR0d2a0F4djIwYzdNaEZ4Nl9JVkIzT0xRUjVpbHJCMGZMOWNaWUkwd2dQMTBab1ZCdjdrMGFkT0RwSWhTMmJwZUxPMXBLc054NzQxZkttQWFRNjZfWHVET3VBRzg?oc=5","date":"2022-01-28","type":"pipeline","source":"BioWorld News","summary":"Big pharma puts bets on alpha-synuclein in Parkinson’s – but will they pay off? - BioWorld News","headline":"Big pharma puts bets on alpha-synuclein in Parkinson’s – but will they pay off?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9TUFQzZl95TW0zQS1zczhMVVRTcDZqU3J3dXVyejk3ckRseXFRd3g4ZmlkXy0ta3k3bzE5aVQxRUxBNTJQWDFnVjBPSVh1VlBORTV0bU5yRU9UNjdQSVlvNA?oc=5","date":"2021-12-06","type":"deal","source":"Cure Parkinson's","summary":"ADepTing to the UCB-Novartis deal - Cure Parkinson's","headline":"ADepTing to the UCB-Novartis deal - Cure Parkinson's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTFBmam5YVVN1YW13VEtMc1pNUV84OGVDaVNlZUtteXpDTWo5akdUa1hXXzgwYXhsV18ySDN5ajAyZS1IZzgyX3JVTzBnVm82LU5rNUp6eg?oc=5","date":"2021-04-26","type":"pipeline","source":"Cure Parkinson's","summary":"UCB at ANN looks A-OK - Cure Parkinson's","headline":"UCB at ANN looks A-OK - Cure Parkinson's","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}